Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1591MR)

This product GTTS-WQ1591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Facioscapulohumeral muscular dystrophy (FSHMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1591MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4448MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ13780MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ14793MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ1359MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ14124MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ10607MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ3466MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ2702MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW